⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9633951 | 1.00 | — | — | |
| SCHEMBL1659298 | 1.00 | — | — | |
| SCHEMBL1659301 | 0.84 | — | — | |
| SCHEMBL2632429 | 0.84 | — | — | |
| SCHEMBL12204195 | 0.74 | — | — | |
| SCHEMBL2624937 | 0.72 | — | — | |
| SCHEMBL715768 | 0.69 | — | — | |
| SCHEMBL8028062 | 0.69 | — | — | |
| SCHEMBL7763088 | 0.69 | — | — | |
| SCHEMBL1339766 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3083943-A | — | — | None | — | — | JP | disclosed |
| CN-107027306-B | 1- (cyclopent-2-en-1-yl) -3- (2-hydroxy-3- (arylsulfonyl) phenyl) urea derivatives as CXCR2 inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-02 | — | — | US | disclosed |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-02 | — | — | US | disclosed |
| US-20190010135-A1 | Novel Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-10 | — | — | US | disclosed |
| US-10106515-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-23 | — | — | US | disclosed |
| EP-3148963-B1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-06-13 | — | — | EP | disclosed |
| US-20170224679-A1 | Use of CXCR2 Antagonists For The Prevention and/or Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-10 | — | — | US | disclosed |
| US-20170224679-A1 | Use of CXCR2 Antagonists For The Prevention and/or Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-10 | — | — | US | disclosed |
| US-20170224679-A1 | Use of CXCR2 Antagonists For The Prevention and/or Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-10 | — | — | US | disclosed |
| EP-3174851-A1 | USE OF CXCR2 ANTAGONISTS FOR THE PREVENTION AND/OR TREATMENT OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY (CIPN) | GlaxoSmithKline Intellectual Property Management Limited (GB) | 2017-06-07 | — | — | EP | disclosed |
| EP-3148963-A1 | 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| WO-2016016178-A1 | USE OF CXCR2 ANTAGONISTS FOR THE PREVENTION AND/OR TREATMENT OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY (CIPN) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016016178-A1 | USE OF CXCR2 ANTAGONISTS FOR THE PREVENTION AND/OR TREATMENT OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY (CIPN) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-02-04 | — | — | WO | disclosed |
| WO-2015181186-A1 | 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | WO | disclosed |
| WO-2015181186-A1 | 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | WO | disclosed |
| EP-0414453-B1 | Optically active cyclopentenols and process for preparing the same | CHISSO CORP (JP) | 1994-02-23 | — | — | EP | disclosed |
| US-5107039-A | Intermediates for asymmetric synthesis of steroids and alkaloids | CHISSO CORPORATION (JP) | 1992-04-21 | — | — | US | disclosed |
| JP-H0383943-A | OPTICALLY ACTIVE CYCLOPENTENOL | CHISSO CORP | 1991-04-09 | — | — | JP | disclosed |
| EP-0414453-A1 | Optically active cyclopentenols and process for preparing the same | Chisso Corporation (JP) | 1991-02-27 | — | — | EP | disclosed |